How to buy NGM Biopharmaceuticals stock (NGM)

NGM Biopharmaceuticals is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 138 staff and has a trailing 12-month revenue of around $4.4 million.

Our top picks for where to buy NGM Biopharmaceuticals stock

Buy NGM Biopharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

NGM Biopharmaceuticals stock price (NASDAQ: NGM)

Use our graph to track the performance of NGM stocks over time.

NGM Biopharmaceuticals shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.83 - $2.20
50-day moving average more info button	$1.55
200-day moving average more info button	$1.47
Wall St. target price	$1.66
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.73

Is it a good time to buy NGM Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NGM Biopharmaceuticals financials

Revenue TTM	$4.4 million
Gross profit TTM	$-125,734,000
Return on assets TTM	-38.46%
Return on equity TTM	-69.76%
Profit margin	0%
Book value	$1.79
Market Capitalization more info button	$128.5 million

TTM: trailing 12 months

NGM Biopharmaceuticals share dividends

We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.

NGM Biopharmaceuticals share price volatility

Over the last 12 months, NGM Biopharmaceuticals's shares have ranged in value from as little as $0.8288 up to $2.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NGM Biopharmaceuticals's is 1.261. This would suggest that NGM Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NGM Biopharmaceuticals overview

NGM Biopharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. ; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc.

Frequently asked questions

What percentage of NGM Biopharmaceuticals is owned by insiders or institutions?
Currently 21.084% of NGM Biopharmaceuticals shares are held by insiders and 54.164% by institutions. How many people work for NGM Biopharmaceuticals?
Latest data suggests 138 work at NGM Biopharmaceuticals. When does the fiscal year end for NGM Biopharmaceuticals?
NGM Biopharmaceuticals's fiscal year ends in December. Where is NGM Biopharmaceuticals based?
NGM Biopharmaceuticals's address is: 333 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is NGM Biopharmaceuticals's ISIN number?
NGM Biopharmaceuticals's international securities identification number is: US62921N1054 What is NGM Biopharmaceuticals's CUSIP number?
NGM Biopharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 62921N105